Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 774
- Registration Number
- NCT00548548
- Locations
- 🇺🇸
Cancer Center of Kansas, Wichita, Kansas, United States
🇺🇸Georgetown University, Washington, D.C., District of Columbia, United States
🇺🇸USC/Norris Cancer Center, Los Angeles, California, United States
High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2015-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 22
- Registration Number
- NCT00547547
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸South Pasadena Cancer Center, Pasadena, California, United States
Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Hopital Jean Minjoz
- Target Recruit Count
- 47
- Registration Number
- NCT00544011
- Locations
- 🇫🇷
Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besancon, France
Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00543842
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery
- Conditions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 19
- Registration Number
- NCT00541112
- Locations
- 🇫🇷
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France
🇫🇷Institut Bergonie, Bordeaux, France
🇫🇷Centre Rene Huguenin, Saint Cloud, France
BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 139
- Registration Number
- NCT00540800
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B, Napoli, Italy
🇮🇹Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C, Napoli, Italy
🇮🇹Ospedale S. Luca ASL SA 3, Vallo della Lucania, Italy
Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2014-08-28
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 13
- Registration Number
- NCT00538291
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸City of Hope Medical Group, Pasadena, California, United States
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00536809
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- Accelerated Community Oncology Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT00534417
- Locations
- 🇺🇸
Augusta Oncology Associates, Augusta, Georgia, United States
🇺🇸Medical & Surgical Specialists, Galesburg, Illinois, United States
🇺🇸Oncology Specialists, Park Ridge, Illinois, United States
Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- Branimir Sikic
- Target Recruit Count
- 13
- Registration Number
- NCT00532909
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.